Kimia biosciences Limited has secured a significant patent grant from The Patent Office, Government of India, strengthening its position in the antifungal pharmaceutical segment. The company announced this development through a regulatory filing to BSE Limited on February 10, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent Details and Specifications

The patent, officially numbered 579384, covers an "Improved Process for the Preparation of Luliconazole," an important antifungal active pharmaceutical ingredient (API). The patent certificate confirms the grant for a standard term of 20 years, effective from the original filing date.

Strategic Impact on Business Portfolio

The patent grant represents a significant addition to Kimia Biosciences' intellectual property portfolio, particularly in the antifungal API segment. According to the company's regulatory communication, this patent is expected to enhance long-term business prospects by providing exclusive rights to the improved manufacturing process for Luliconazole.

Luliconazole is a topical antifungal medication used to treat various fungal skin infections. The patent covers an improved preparation process, which could potentially offer manufacturing advantages such as enhanced efficiency, better yield, or improved product quality compared to existing methods.

Regulatory Compliance and Documentation

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signing the disclosure document. The filing includes the complete patent certificate as supporting documentation, ensuring full transparency with stakeholders and regulatory authorities.

Patent Maintenance Requirements

The patent certificate specifies that renewal fees for maintaining the patent will be due on January 9, 2024, and annually thereafter on the same date. This ongoing financial commitment will be necessary to preserve the exclusive rights throughout the 20-year patent term.

This patent grant positions Kimia Biosciences Limited to potentially leverage its proprietary process technology in the competitive antifungal API market, providing a foundation for future business development and market expansion opportunities.

Kimia biosciences Limited has announced a board meeting scheduled for February 14, 2026, to address key corporate matters including quarterly financial results and executive leadership continuity. The pharmaceutical company informed BSE Limited about the upcoming board deliberations through a regulatory filing dated February 7, 2026.

Board Meeting Agenda

The board meeting will focus on two primary items requiring director approval:

Managing Director Re-appointment

The board will consider the re-appointment of Mr. Sameer Goel (DIN: 00161786) as Managing Director for an extended five-year period. His current tenure concludes on March 28, 2026, and the proposed re-appointment would commence immediately thereafter on March 29, 2026. The re-appointment remains subject to shareholder approval in accordance with the Companies Act, 2013 and applicable SEBI regulations.

Trading Window Restrictions

Kimia Biosciences has implemented trading window restrictions in compliance with insider trading regulations. The company closed the trading window effective January 1, 2026, for all designated persons including intermediaries and relatives. This closure applies specifically to the declaration of unaudited financial results for the quarter and nine months ended December 31, 2025.

Corporate Information

The company maintains its registered office and manufacturing works at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. Its corporate office operates from Aggarwal Millennium Tower-II in Netaji Subhash Place, Pitampura, New Delhi. Company Secretary and Compliance Officer Pallavi Garg signed the regulatory communication, ensuring compliance with listing obligations and disclosure requirements under SEBI regulations.